Table 2 Univariate and multivariate analyses of overall survival according to clinicopathologic factors

Sex

 Male versus female

1.014 (0.616–1.669)

Age, y

  < 60 versus ≥ 60

2.047 (1.280–3.274)

2.075 (1.261–3.414)

Smoking history

 No versus yes

1.119 (0.737–1.700)

Drinking history

 No versus yes

0.863 (0.562–1.325)

Primary location

 Upper

1.000

1.000

 Middle

1.020 (0.565–1.844)

0.985 (0.509–1.909)

 Low

0.456 (0.279–0.746)

0.400 (0.235–0.680)

Borrmann type

 Type I–II versus III–IV

1.482 (0.898–2.445)

Pathological type

 Adenocarcinoma versus mucinous/rare carcinoma

0.959 (0.596–1.544)

Histologic type

 Well/moderate versus poor

1.163 (0.723–1.871)

Neural invasion

 Negative versus positive

1.912 (1.080–3.388)

1.695 (0.915–3.141)

Lymphovascular invasion

 Negative versus positive

1.526 (0.899–2.592)

Depth of tumor invasion

 sMP versus dMP

1.805 (1.166–2.796)

1.584 (1.000–2.509)

pN stage

 N0

1.000

1.000

 N1

2.543 (1.542–4.193)

2.304 (1.364–3.890)

 N2

2.558 (1.393–4.698)

1.879 (0.967–3.652)

 N3

4.948 (2.502–9.787)

5.335 (2.533–11.237)

Adjuvant chemotherapy

 Without versus with

0.890 (0.583–1.360)

HER-2/neu expression

 Negative versus positive

0.996 (0.593–1.672)

P53 expression

 Negative versus positive

2.288 (1.440–3.637)

1.793 (1.117–2.879)

VEGF expression

 Negative versus positive

1.069 (0.647–1.768)

EGFR expression

 Negative versus positive

0.919 (0.586–1.441)

Initial LDH level (U/L)

  < 245 versus ≥ 245

1.230 (0.389–3.890)

Maximal LDH level (U/L)

  < 245 versus ≥ 245

1.443 (0.950–2.193)

1.688 (1.066–2.672)

Initial CEA level (ng/mL)

  < 3.5 versus ≥ 3.5

1.664 (1.071–2.587)

0.987 (0.617–1.577)

Initial CA125 level (U/mL)

  < 35 versus ≥ 35

1.649 (0.521–5.218)

Initial CA19-9 level (U/mL)

  < 39 versus ≥ 39

2.450 (1.229–4.883)

3.572 (1.735–7.358)

Initial AFP level (ng/mL)

  < 7 versus ≥ 7

2.387 (1.235–4.614)

2.033 (1.004–4.116)